In light of the encouraging preclinical data reported by our group and others, which provide compelling evidence for the role of DYRK1A signalling in the cognitive impairment in DS, it has indeed become a viable option to initiate testing of DYRK1A inhibitors in the clinical setting. The gene discussed is DYRK1A; the disease is Dravet syndrome.